On May 27, 2020 Bold Therapeutics, a clinical-stage biopharmaceutical company, reported it has executed an option agreement with an undisclosed publicly traded company for exclusive rights to BOLD-100 in South Korea (Press release, Bold Therapeutics, MAY 27, 2020, View Source [SID1234558585]). BOLD-100 is a first-in-class anti-resistance ruthenium-based small molecule drug which selectively inhibits stress-induced upregulation of GRP78 – an important resistance, survival and proliferation pathway common across cancers. Under the terms of the agreement, Bold Therapeutics and its new partner will collaborate on Bold Therapeutics’ upcoming Phase 1b / 2a adaptive trial in gastric, pancreatic, colorectal and bile duct (cholangiocarinoma) cancers – and explore the potential development of BOLD-100 in triple-negative breast cancer (TNBC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"I am pleased to partner with one of the fastest growing and most successful pharmaceutical companies in South Korea on the development of BOLD-100. This collaboration allows us to leverage our partner’s significant oncology development and commercialization expertise in South Korea to accelerate development of BOLD-100," stated E. Russell McAllister, CEO of Bold Therapeutics. "Under this collaboration, we expect to both add clinical sites in South Korea to our planned Phase 1b / 2a adaptive trial by early 2021, potentially accelerating enrollment and the resulting timing of interim efficacy data, as well as add triple-negative breast cancer (TNBC), an indication where our partner has significant expertise, as a potential development indication – the first of many win-win partnerships."

Jim Pankovich, EVP of Clinical Development at Bold Therapeutics, added, "The quality of clinical data from South Korea is viewed favorably throughout the world. This promising partnership speaks to BOLD-100’s remarkable potential and allows us to generate data in an Asian population earlier than would otherwise have been possible. I look forward to working with our new clinical and regulatory colleagues in the coming weeks."

On May 27, 2020 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) reported that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $250,000,000 of its common stock (Press release, Arena Pharmaceuticals, MAY 27, 2020, View Source [SID1234558584]). All of the shares are being offered by Arena . In addition, Arena intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BofA Securities, Citigroup and SVB Leerink are acting as the joint book-running managers for the offering. Credit Suisse and Cantor are also acting as book-running managers for the offering. JMP Securities and Needham & Company are acting as co-managers for the offering.

The shares of common stock described above are being offered by Arena pursuant to a shelf registration statement filed by Arena with the Securities and Exchange Commission (SEC) that became automatically effective on February 27, 2020. A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC’s website located at View Source Copies of the preliminary prospectus supplement and the accompanying prospectus related to this offering, when available, may be obtained from BofA Securities, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at [email protected]; or from Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (800) 831-9146; or from SVB Leerink, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext. 6218, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

On May 27, 2020 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) reported that the company will webcast its corporate presentations at the following virtual investor conferences (Press release, Jazz Pharmaceuticals, MAY 27, 2020, View Source [SID1234558583]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 4:30 p.m. EDT / 9:30 p.m. IST. Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update.
Goldman Sachs Virtual Healthcare Conference on Wednesday, June 10, 2020 at 11:20 a.m. EDT / 4:20 p.m. IST. Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business and financial update.
A live audio webcast of each presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of each presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast.

An archive of each webcast will be available for at least one week following each presentation on the Investors section of the company’s website at www.jazzpharmaceuticals.com.

On May 27, 2020 Varian (NYSE: VAR) reported that J. Michael Bruff, Chief Financial Officer, Chris Toth, President, Varian Oncology Systems, and Anshul Maheshwari, Vice President, Investor Relations and Treasurer will participate in a virtual fireside chat at the Jefferies Virtual Healthcare Conference, scheduled for 11:00 a.m. Eastern Time on Tuesday, June 2, 2020 (Press release, Varian Medical Systems, MAY 27, 2020, View Source [SID1234558582]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Information about the webcast of the company’s presentation will be available through a link on the company website at www.varian.com/investors.

On May 27, 2020 Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, reported the pricing of an underwritten public offering of 753,012 shares of its common stock at a price to the public of $166.00 per share (Press release, Penumbra, MAY 27, 2020, View Source [SID1234558581]). All of the shares of common stock to be sold in the offering will be offered by Penumbra. The offering is scheduled to close on June 1, 2020, subject to customary closing conditions. The underwriters for the offering will also have a 30-day option to purchase up to an additional 112,951 shares of Penumbra’s common stock at the public offering price, less underwriting discounts and commissions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Penumbra intends to use the net proceeds from this offering for general corporate purposes, including working capital, continued development of its products, including research and development and clinical trials, potential acquisitions and other business opportunities.

J.P. Morgan and BofA Securities are acting as joint lead book-running managers for the offering. Canaccord Genuity, Wells Fargo Securities and Citigroup are acting as co-managers for the offering. Perella Weinberg Partners is acting as independent capital markets advisor to Penumbra for the offering.

A registration statement (including a base prospectus) and a preliminary prospectus supplement relating to these securities has been filed with the Securities and Exchange Commission. The registration statement became effective on February 26, 2020. The offering is being made only by means of a prospectus supplement (including the accompanying base prospectus), copies of which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-212-834-4533, or by emailing at [email protected]; or BofA Securities, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte NC 28255-0001, Attn: Prospectus Department, or email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.